Characteristics | n (%) | P value* | |
MISTIE group (n=146) | SMC group (n=164) | ||
Age, mean (SD), years | 60.7 (11.6) | 61.6 (13.0) | 0.50 |
Sex | |||
Female | 48 (32.9) | 69 (42.1) | 0.10 |
Male | 98 (67.1) | 95 (57.9) | |
Race and ethnicity† | |||
Black | 26 (17.8) | 27 (16.5) | 0.43 |
Hispanic/Latino | 25 (17.1) | 26 (15.9) | |
White | 88 (60.3) | 96 (58.5) | |
Other‡ | 7 (4.8) | 16 (10.4) | |
Hypertension | 140 (95.9) | 157 (95.7) | 0.94 |
Diabetes | 44 (30.1) | 49 (29.9) | 0.96 |
Hyperlipidaemia | 52 (35.6) | 66 (40.2) | 0.40 |
Tobacco use | 25 (17.1) | 26 (15.9) | 0.76 |
Cocaine use | 4 (2.7) | 7 (4.3) | 0.47 |
Previous anticoagulant use | 10 (6.8) | 8 (4.9) | 0.46 |
Previous antiplatelet use | 45 (30.8) | 54 (32.9) | 0.69 |
Clinical severity factor | |||
GCS score at randomisation§ | 10 (8, 12) | 10 (8, 13) | 0.67 |
ICH location | |||
Lobar | 45 (30.8) | 70 (42.7) | 0.03 |
Deep | 101 (69.2) | 94 (57.3) | |
Parenchymal ICH volume on admission, mL§ | 46.8 (33.2–59.8) | 45.8 (34–59.5) | 0.87 |
IVH volume on admission, mL§ | 1.1 (0–5.2) | 0.6 (0–3.8) | 0.24 |
Parenchymal ICH volume at stability, mL§ | 51.6 (39.9–64.4) | 50.3 (38.4–62.8) | 0.38 |
IVH volume at stability, mL§ | 2.2 (0.7–5.9) | 2.0 (0.5–4.9) | 0.39 |
End-of-treatment parenchymal ICH volume, mL§ | 15.3 (8.9–21.8) | 46.9 (37.1–60.6) | <0.0001 |
End-of-treatment IVH volume, mL§ | 0.9 (0.3–2.7) | 1.3 (0.3–3.0) | 0.29 |
EVD use | 33 (22.6) | 25 (15.2) | 0.10 |
Time interval from ictus to end-of-treatment CT scan, hours§ | 125.5 (104–157.5) | 116 (103–127) | 0.0001 |
Number of doses of study agent§ | 4 (3, 7) | n/a | n/a |
Time interval from ictus to first dose of study agent, hours§ | 71 (56–82) | n/a | n/a |
*P<0.05 was considered statistically significant.
†Race and ethnicity were investigator reported in the MISTIE-III trial.
‡Other included Asian, Native American, Native Hawaiian or other Pacific Islander.
§Indicates values presented as median (IQR).
EVD, external ventricular drainage; GCS, Glasgow Coma Scale; ICH, intracerebral haemorrhage; IVH, intraventricular haemorrhage; MISTIE-III, Minimally Invasive Surgery plus Alteplase for Intracerebral Hemorrhage Evacuation Phase III; SMC, standard medical care.